Ozempic and Wegovy are both semaglutide, made by Novo Nordisk, and both are once-weekly injections. The difference is the label: Ozempic is FDA-approved for type 2 diabetes (and to reduce cardiovascular risk), while Wegovy is approved for chronic weight management (and to reduce cardiovascular risk). Wegovy is dosed higher for weight loss — up to 2.4 mg — versus up to 2 mg for Ozempic. Ozempic is often prescribed off-label for weight loss, but only Wegovy is studied and approved at the weight-management dose. Which one fits you is a decision for your clinician.
Key takeaways
- Same active ingredient (semaglutide), same manufacturer (Novo Nordisk), same once-weekly injection.
- Different approved uses: Ozempic for type 2 diabetes; Wegovy for chronic weight management.
- Different top doses: Ozempic up to 2 mg; Wegovy up to 2.4 mg. Wegovy averaged about 15% body-weight loss in the STEP trials.
- Different coverage rules mean cost and insurance approval can diverge sharply — confirm current details before you commit.
Are Ozempic and Wegovy the same drug?
Yes. Both Ozempic and Wegovy contain semaglutide, a GLP-1 receptor agonist made by Novo Nordisk, and both are given as a once-weekly subcutaneous injection. If you compared the molecules under a microscope, they would be identical. That's the single most important thing to understand: this is not a "which drug is stronger" question in the usual sense, because it's the same drug.
What Novo Nordisk did was develop and study semaglutide for two different purposes and bring it to market under two different brand names, at two different dose ranges, with two different sets of clinical trials behind them. Ozempic came first, studied and approved for blood-sugar control in type 2 diabetes. Wegovy followed, studied at a higher dose specifically for weight management. Same engine, two different vehicles.
Ozempic vs Wegovy: the side-by-side
Here's how the two products line up on the details that actually matter when you and a clinician are weighing options.
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Maker | Novo Nordisk | Novo Nordisk |
| FDA-approved use | Type 2 diabetes; reducing cardiovascular risk | Chronic weight management; reducing cardiovascular risk |
| Form & frequency | Once-weekly injection | Once-weekly injection |
| Maximum dose | Up to 2 mg | Up to 2.4 mg (standard weight-management dose) |
| Average weight loss in trials | Studied for glucose control, not the weight-management indication | ~15% of body weight (STEP trials) |
| Typical cost / coverage | Often covered under diabetes benefits; varies by plan | Coverage for weight management varies widely; often stricter |
Note the last two rows are where the real-world differences live. Because the drug is identical, most of the decision comes down to your medical situation, what your insurance will approve, and how the two products are dosed and priced at any given moment.
Why the doses differ
Ozempic titrates up to a maximum of 2 mg once weekly, while Wegovy titrates up to 2.4 mg — a higher ceiling chosen because the weight-management trials studied that dose. Both start low and step up over weeks to limit gastrointestinal side effects, which is standard for every GLP-1. Our dosing and titration guide walks through the general schedules, but the specific steps differ between the two products, which is exactly why switching between them isn't a simple swap.
Novo Nordisk has also continued to expand the semaglutide portfolio over time, including higher-dose options for weight management. Because the exact dose forms and their availability change, the most reliable source for what's currently on the market is the FDA prescribing information and the manufacturer's materials — check those rather than assuming.
What about weight loss specifically?
Wegovy is the semaglutide product FDA-approved for chronic weight management, and in the STEP trial program it produced average weight loss of roughly 15% of body weight — though individual results vary widely, and those results came alongside diet and activity changes. You can read more in our GLP-1 and weight loss overview.
Ozempic is frequently prescribed off-label for weight loss, and because it is the same molecule, it acts on appetite and gastric emptying the same way. The catch is that Ozempic's approved dose ceiling is lower (2 mg vs 2.4 mg), and its weight-loss use hasn't been through the dedicated approval process that Wegovy has. Off-label prescribing is legal and common, but it's a clinical judgment call, not a shortcut. If you want to estimate a realistic range for yourself, our weight-loss calculator can help set expectations.
Which is right for you?
There's no universal winner here — the "better" choice depends entirely on your circumstances:
- If you have type 2 diabetes, Ozempic is the on-label semaglutide, and diabetes coverage is often more straightforward.
- If your goal is weight management and you don't have diabetes, Wegovy is the on-label option studied at the higher weight-loss dose.
- If coverage or cost is the deciding factor, what your plan will actually approve for your diagnosis may matter more than the drug itself.
- If you're already on one and considering the other, that's a planned transition with your prescriber, not a self-directed switch.
All of this is general education. The prescription, the indication, and the dose are decisions you make with a clinician who knows your history. For a broader map of the whole category, see our guide to all GLP-1 medications.
Frequently asked questions
Are Ozempic and Wegovy the same drug?
Yes — both contain the same active ingredient, semaglutide, and are made by Novo Nordisk. The difference is what each is FDA-approved to treat, the doses available, and the branding. Ozempic is approved for type 2 diabetes, while Wegovy is approved for chronic weight management.
Which is better for weight loss, Ozempic or Wegovy?
Wegovy is the one FDA-approved specifically for weight management and is dosed higher for that purpose (up to 2.4 mg), whereas Ozempic is approved for diabetes and dosed up to 2 mg. Because they're the same molecule they work the same way, but only Wegovy has been studied and approved at the higher weight-management dose. The right choice is individual and decided with a clinician.
Can you get Ozempic for weight loss?
Ozempic is frequently prescribed off-label for weight loss because it's the same molecule as Wegovy, but it's FDA-approved for type 2 diabetes rather than weight management. Off-label prescribing is legal and common, but insurance coverage, dosing and cost differ from the on-label weight-management product. This is general education, not medical advice.
Do Ozempic and Wegovy cost the same?
Not necessarily. List prices, insurance coverage and out-of-pocket cost differ between the two products and change frequently, partly because they're approved for different indications. Diabetes coverage for Ozempic and weight-management coverage for Wegovy follow different insurance rules. Always confirm current pricing with your pharmacy, the manufacturer program and your plan.
Can I switch between Ozempic and Wegovy?
Because both are semaglutide, clinicians sometimes transition patients between them, but the dose forms and titration schedules differ, so it's not a simple one-to-one swap. Any switch should be planned with your prescriber, who will map your current dose to the appropriate dose of the other product.
Sources & further reading
- U.S. Food & Drug Administration — prescribing information for Ozempic (semaglutide) and Wegovy (semaglutide).
- Novo Nordisk — product information and dosing materials for Ozempic and Wegovy.
- STEP clinical trial program (semaglutide 2.4 mg) — published weight-management results.